BELITE BIO, INC Logo

BELITE BIO, INC

Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.

BLTE | US

Overview

Corporate Details

ISIN(s):
US07782B1044
LEI:
Country:
United States of America
Address:
12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. The company's primary targets include atrophic age-related macular degeneration (specifically Geographic Atrophy, or GA) and Stargardt disease (STGD1). Its therapeutic pipeline is built on a proprietary portfolio targeting Retinol Binding Protein 4 (RBP4). The lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins that contribute to disease progression. Tinlarebant is in late-stage development with multiple Phase 3 trials and has received numerous regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations in the U.S. and other key markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BELITE BIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden IRLAB
IRONWOOD PHARMACEUTICALS INC Logo
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America IRWD
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea 086890
Iterum Therapeutics plc Logo
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America ITRM
IVF HARTMANN Holding AG Logo
Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.
Switzerland VBSN
Jade Biosciences, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America JBIO
Jaguar Health, Inc. Logo
Develops plant-based, non-opioid GI therapies for humans and animals.
United States of America JAGX
Janux Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
United States of America JANX
Japan Tissue Engineering Co., Ltd. Logo
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan 7774

Talk to a Data Expert

Have a question? We'll get back to you promptly.